Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 5/20 | 0.50 |
| ▸ | CCR2 | P41597 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3872046 | 1.00 | CHRM1 (0.58) | CHRM1DHODHGRM5CCR2L3MBTL1 | |
| SCHEMBL3974004 | 0.89 | CCR2 (0.58) | CHRM1GRM5CCR2L3MBTL1NPC1 | |
| SCHEMBL3974005 | 0.89 | CCR2 (0.58) | CHRM1GRM5CCR2L3MBTL1NPC1 | |
| SCHEMBL3875809 | 0.85 | CCR2 (0.57) | CHRM1DHODHCCR2CACNA1HMEN1 | |
| SCHEMBL3875804 | 0.85 | CCR2 (0.57) | CHRM1DHODHCCR2CACNA1HMEN1 | |
| SCHEMBL3880147 | 0.85 | CCR2 (0.57) | CHRM1DHODHCCR2CACNA1HMEN1 | |
| SCHEMBL3869039 | 0.82 | DHODH (0.57) | DHODHGRM5CCR2L3MBTL1NPC1 | |
| SCHEMBL3869036 | 0.82 | DHODH (0.57) | DHODHGRM5CCR2L3MBTL1NPC1 | |
| SCHEMBL3870254 | 0.79 | EPHX2 (0.63) | MEN1KMT2A | |
| SCHEMBL3869194 | 0.79 | EPHX2 (0.63) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891064-B1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | ALMIRALL SA (ES) | 2009-09-02 | — | — | EP | disclosed |
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-05-21 | — | — | US | disclosed |
| EP-1891064-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | Laboratorios Almirall, S.A. (ES) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006133802-A1 | N-AMIDE DERIVATIVES OF 8-AZABICYCLO[3.2.1]OCT-3-YL AS CCR1 ANTAGONISTS | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130090-A1 | N-amide Derivatives of 8-Azabicyclo[3.2.1]OCT-3-YL AS CCR1 Antagonists | CCR1, CCR3, CCR8 | CHRM1 394/4885DHODH 4148/4885GRM5 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.